% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kutzsche:1014979,
      author       = {Kutzsche, Janine and Schemmert, Sarah and Bujnicki, Tuyen
                      and Zafiu, Christian and Halbgebauer, Steffen and
                      Kraemer-Schulien, Victoria and Pils, Marlene and Blömeke,
                      Lara and Post, Julia and Kulawik, Andreas and Jürgens,
                      Dagmar and Rossberg, Wolfgang M. and Hümpel, Michael and
                      Bannach, Oliver and Otto, Markus and Araujo, Joseph A. and
                      Willuweit, Antje and Willbold, Dieter},
      title        = {{O}ral treatment with the all-d-peptide {RD}2 enhances
                      cognition in aged beagle dogs – {A} model of sporadic
                      {A}lzheimer’s disease},
      journal      = {Heliyon},
      volume       = {9},
      number       = {8},
      issn         = {2405-8440},
      address      = {London [u.a.]},
      publisher    = {Elsevier},
      reportid     = {FZJ-2023-03523},
      pages        = {e18443 -},
      year         = {2023},
      abstract     = {Disease-modifying therapies to treat Alzheimer's disease
                      (AD) are of fundamental interest for aging humans,
                      societies, and health care systems. Predictable disease
                      progression in transgenic AD models favors preclinical
                      studies employing a preventive study design with an early
                      pre-symptomatic treatment start, instead of assessing a
                      truly curative approach with treatment starting after
                      diagnosed disease onset. The aim of this study was to
                      investigate the pharmacokinetic profile and efficacy of RD2
                      to enhance short-term memory and cognition in cognitively
                      impaired aged Beagle dogs - a non-transgenic model of truly
                      sporadic AD. RD2 has previously demonstrated pharmacodynamic
                      efficacy in three different transgenic AD mouse models in
                      three different laboratories. Here, we demonstrate that oral
                      treatment with RD2 significantly reduced cognitive deficits
                      in cognitively impaired aged Beagle dogs even beyond the
                      treatment end, which suggests in combination with the
                      treatment dependent CSF tau oligomer decrease a
                      disease-modifying effect of RD2 treatment.},
      cin          = {IBI-7},
      ddc          = {000},
      cid          = {I:(DE-Juel1)IBI-7-20200312},
      pnm          = {5244 - Information Processing in Neuronal Networks
                      (POF4-524)},
      pid          = {G:(DE-HGF)POF4-5244},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {37609390},
      UT           = {WOS:001144588100001},
      doi          = {10.1016/j.heliyon.2023.e18443},
      url          = {https://juser.fz-juelich.de/record/1014979},
}